Statin therapy reduces serum levels of glycosylphosphatidylinositol-specific phospholipase D

Vaughan, 2000, The evolving role of statins in the management of atherosclerosis, J Am Coll Cardiol, 35, 1, 10.1016/S0735-1097(99)00525-2

Hoener, 1992, Phosphatidylinositol-glycan-specific phospholipase D is an amphiphilic glycoprotein that in serum is associated with high-density lipoproteins, Eur J. Biochem., 206, 747, 10.1111/j.1432-1033.1992.tb16981.x

Deeg, 2001, GPI-specific phospholipase D associates with an apoA-I- and apoA-IV-containing complex, J Lipid Res, 42, 442, 10.1016/S0022-2275(20)31669-2

Kurtz, 2004, Insulin resistance is associated with increased serum levels of glycosylphosphatidylinositol-specific phospholipase D, Metabolism, 53, 138, 10.1016/j.metabol.2003.09.004

Deeg, 2001, Increased expression of GPI-specific phospholipase D in mouse models of type 1 diabetes, Am J Physiol Endocrinol Metab, 281, E147, 10.1152/ajpendo.2001.281.1.E147

Maguire, 1995, Glycosyl phosphatidyl inositol phospholipase D activity in human serum, An Clin Biochem, 32, 74, 10.1177/000456329503200107

Raymond, 1994, Inositol-specific phospholipase D activity in health and disease, Clin Sci (Colch), 86, 447, 10.1042/cs0860447

Schofield, 2002, Insulin reduces serum glycosylphosphatidylinositol phospholipase D levels in human type I diabetic patients and streptozotocin diabetic rats, Mol Genet Metab, 75, 154, 10.1006/mgme.2001.3287

Chalasani, 2006, Glycosylphosphatidylinositol- specific phospholipase d in nonalcoholic fatty liver disease: a preliminary study, J Clin Endocrinol Metab, 91, 2279, 10.1210/jc.2006-0075

Low, 1991, Factors affecting the ability of glycosylphosphatidylinositol- specific phospholipase D to degrade the membrane anchors of cell surface proteins, Biochem J., 279, 483, 10.1042/bj2790483

Stieger, 1991, Enzymatic properties of phosphatidylinositol- glycan-specific phospholipase C from rat liver and phosphatidylinositol-glycan-specific phospholipase D from rat serum, Eur J Biochem, 197, 67, 10.1111/j.1432-1033.1991.tb15883.x

Raikwar, 2006, Glycosylphosphatidylinositol-specific phospholipase D influences triglyceride-rich lipoprotein metabolism, Am J Physiol Endocrinol Metab, 290, E463, 10.1152/ajpendo.00593.2004

Burnett, 1999, The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs, Endocrinology, 140, 5293, 10.1210/endo.140.11.7150

Forster, 2002, Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates, Atherosclerosis, 164, 129, 10.1016/S0021-9150(02)00052-7

Watts, 2003, Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome, Int J Obes Relat Metab Disord, 27, 862, 10.1038/sj.ijo.0802287

Asztalos, 2003, High-density lipoprotein subpopulations in pathologic conditions, Am J Cardiol, 91, 12E, 10.1016/S0002-9149(02)03383-0

Asztalos, 2002, Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients, J Lipid Res, 43, 1701, 10.1194/jlr.M200037-JLR200

Asztalos, 2002, Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients, Atherosclerosis, 164, 361, 10.1016/S0021-9150(02)00149-1

Shao, 2006, Pathways for oxidation of high- density lipoprotein in human cardiovascular disease, Curr Opin Mol Ther, 8, 198

Huptas, 2006, Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome, Am J Cardiol, 98, 66, 10.1016/j.amjcard.2006.01.055